Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Cingulate Inc. Common Stock
CING | US
4.92
USD0.33
7.19%
CING | US
About Cingulate Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
4.92
Open
4.65
High
4.94
Low
4.55
Cingulate Inc. a clinical-stage biopharmaceutical company focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate) which is in phase 3 clinical trial and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children adolescents and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City Kansas.
View LessCING | US
Risk
62.5
Sharpe
-0.25
Luna's Score
46/100
Recommendation
Hold
Luna says (CING | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
81.6%1 month
62.5%3 months
640.6%6 months
478.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.53
Debt to equity
0.11
Debt to assets
0.06
Ent. to EBITDA
-0.36
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-18.05M
MarketCap
14.98M
MarketCap(USD)
14.98M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-1.36K
Short ratio
0.05
Short perc.
0.95
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.84
Range1M
1.12
Range3M
20.62
Volumes: Market Activity
Rel. volume
0.94
Price X volume
550.14K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.36 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.53 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 640.57 | - | Riskier |
| Debt to Equity | 0.11 | -1.23 | Expensive |
| Debt to Assets | 0.06 | 0.25 | Cheaper |
| Market Cap | 14.98M | - | Emerging |
